The Promise of Proteomics
When your state is home to two of the top three university analytical
chemistry departments and you have a major pharmaceutical powerhouse
in the mix, what do you do to utilize that expertise? You establish
the Indiana Proteomics Consortium (IPC).
Indiana University, Purdue University and Eli Lilly and Company,
one of the largest developers of protein therapeutics in the pharmaceutical
industry, joined forces in 2002 to pool their expertise and provide
a focused environment for research, communication and biomedical
application.
Proteomics is the identification, characterization and quantification
of all proteins involved in a particular cell, tissue or organ that
can be studied in concert to provide accurate and comprehensive
data about that system.
Today, proteomics is at the forefront as researchers seek to unlock
the chemical mysteries of disease and health. The IPC seeks to develop
novel instrumentation and methodologies to solve these scientific
“who-dun-its.”
Two of IU’s top scientists from Bloomington are principal
investigators for the consortium: Milos V. Novotny, PhD, Distinguished
Professor and the Lilly Chemistry Alumni Chair of Bioanalytical
Chemistry and Chemical Biology; and James P. Reilly, PhD, professor
of physical and analytical chemistry.
The IPC leadership is John G. Hurrell, PhD, president, and Brent
Boeckmann, vice president of business development. Its board of
managers includes Dr. Hurrell; IUSM Dean D. Craig Brater, MD; Richard
DiMarchi, PhD; Jack Gill, chairman of the Gill Foundation of Texas;
V. William Hunt, JD, chairman of Hunt Capital Partners, LLC; Peter
T. Kissinger, PhD, chairman and CEO of Bioanalytical Systems Inc.;
and Sally Frost Mason, PhD, Purdue provost and professor of biology.
For more information about the Indiana Proteomics Consortium,
go to www.inproteomics.com.
|
